Glucagon receptor antagonists, preparation and therapeutic uses

A compound structurally represented by Formula I

• or a pharmaceutically acceptable salt thereof wherein:
• T is carbon or nitrogen;
• R1 and R2 are independently —H or -halogen;
• R3 is
• —(C1-C8)alkyl (optionally substituted with 1 to 3 halogens), —(C2-C7)alkenyl (optionally substituted with 1 to 3 halogens), —(C3-C7)cycloalkyl,
• —(C1-C6)alkyl-(C3-C7)cycloalkyl, or
• —(C3-C7)cycloalkyl-(C1-C6)alkyl (optionally substituted with 1 to 3 halogens);
• R4 and R5 are independently
• —H, -halogen, -hydroxy, hydroxymethyl, —CN, —(C1-C7)alkoxy,
• —(C2-C7)alkenyl, or —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens);
• R6 is
• wherein the zig-zag mark shows the point of attachment to the parent molecule;
• R7 and R8 are independently
• —H, -halogen, —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens),
• —(C1-C6)alkoxy, —(C3-C7)cycloalkyl, —C(O)R10, —COOR10, —OC(O)R10,
• —OS(O)2R10, —SR10, —S(O)R10, —S(O)2R10, or —O(C2-C7)alkenyl;
• R9 is independently
• —H, halogen, —CN, —(C3-C7)cycloalkyl, —C(O)R10, —COOR10, —OC(O)R10,
• —OS(O)2R10, —SR10, —S(O)R10, —S(O)2R10, or —O(C2-C7)alkenyl, —(C1-C3)alkoxy (optionally substituted with 1 to 3 halogens), or —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens);
• R10 is independently at each occurrence
• -hydrogen, or —(C1-C6)alkyl (optionally substituted with 1 to 3 halogens);
• and
• R11 is independently
• —H, —(C1-C8)alkyl (optionally substituted with 1 to 3 halogens), or —(C2-C7)alkenyl (optionally substituted with 1 to 3 halogens);
• provided however that if R11 is —(C1-C8)alkyl (optionally substituted with 1 to 3 halogens), or —(C2-C7)alkenyl (optionally substituted with 1 to 3 halogens) then R3 is the same moiety as R11;
• or R11 and R3 together with the carbon to which they are attached form a cycloalkyl ring having five carbons (wherein optionally the cycloalkyl ring having five carbons may contain one double bond).